8,749
Total Claims
$713K
Drug Cost
785
Beneficiaries
$908
Cost/Patient
Peer Comparison vs. 4,479 Interventional Cardiology providers
-14%
Cost per patient vs peers
$908 vs $1,054 avg
-21%
Brand preference vs peers
10.3% vs 13.1% avg
Brand vs Generic
90% generic
Brand: 905 claims · $593K
Generic: 7,844 claims · $120K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 232 | $218K |
| Rivaroxaban | 106 | $77K |
| Sacubitril/Valsartan | 54 | $60K |
| Dapagliflozin Propanediol | 66 | $52K |
| Evolocumab | 46 | $40K |
| Semaglutide | 39 | $40K |
| Tirzepatide | 17 | $22K |
| Ticagrelor | 32 | $16K |
| Alirocumab | 18 | $14K |
| Pitavastatin Calcium | 24 | $13K |
| Empagliflozin | 14 | $11K |
| Rosuvastatin Calcium | 619 | $9,159 |
| Ranolazine | 100 | $8,659 |
| Potassium Chloride | 504 | $8,628 |
| Icosapent Ethyl | 21 | $7,993 |
Prescribing Profile
Patient Profile
75
Avg Age
60%
Female
1.39
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About